Navigation Links
Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Date:6/7/2012

WORCESTER, Mass. and TORONTO, June 7, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that an End-of-Phase II meeting has been scheduled with the United States Food and Drug Administration (FDA) in respect of the Phase II clinical trial of the AE37 breast cancer vaccine being undertaken by its wholly-owned subsidiary, Antigen Express, Inc.

The meeting has been scheduled for June 18, 2012 with FDA regulatory management staff in the Office of Cellular Tissues and Gene Therapies in the Center for Biologics Evaluation and Research.  Antigen Express has provided the FDA with a comprehensive and detailed package regarding the AE37 breast cancer vaccine, the on-going Phase II clinical trial, and the company's plans for a transition into a pivotal Phase III trial.

Antigen Express will solicit guidance from the FDA regarding the company's proposed structure of a pivotal Phase III trial.

In addition to representatives of Antigen Express, Dr. Samuel Jacobs, MD, Director, Medical Affairs, National Surgical Adjuvant Breast and Bowel Project (NSABP) and a member of the Antigen Express AE37 breast cancer Scientific Advisory Board (SAB), will attend the meeting to proffer his advice and assistance on behalf of Antigen Express.  The NSABP is a clinical trials cooperative group supported since its inception by the National Cancer Institute (NCI). It has a more than 50-year history of designing and conducting clinical trials that have changed the way breast cancer is treated, and, more recently, prevented.  The NSABP was the first to demonstrate that adjuvant therapy could alter the natural history of breast cancer.  Since its inception, the NSABP has enrolled more than 110,000 women and men in clinical trials in breast and colorectal cancer.  It has research sites at nearly 1000 major medical centers, university hospitals, large oncol
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
4. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
5. Generex Secures Commitments for $3.6M Capital Raise
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
8. Generex Announces Date of Annual Stockholders Meeting
9. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 ... that it will be participating in the Jefferies 2015 ... on Tuesday, June 2, 2015. Jeff ... question and answer session at 10:00 a.m. ET (3:00 ... be available on the Presentations and Webcasts section of ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Assessments of Leading Microbiology ... Recent Market Entrants" report to their ... from VPGMarketResearch.com provides insightful profiles of leading ... The report presents strategic assessments, ...
(Date:5/31/2015)... BARCELONA, Spain , June 1, 2015 /PRNewswire/ ... company dedicated to rare diseases, has selected Veeva ... across sales, marketing, and medical. A complete solution, ... data, multichannel interactions, and compliant content to provide ... and effective commercial execution.      (Logo: ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The ... novel research for bile duct cancer, announced today ... Research Fellowship Program. , The Foundation ... scientists throughout the country to raise awareness about ... will support research that opens new pathways for ...
Breaking Biology Technology:Assessments of Leading Microbiology Market Players 2015 - Profiles of Major Suppliers and Recent Market Entrants 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3
... year,s first , quarter , - Total revenue of ... million , - Earnings per share of $0.29, an increase of ... - New products launched containing life,sDHA(TM) in a variety of , ... demonstrate the strong , leverage in our businessCOLUMBIA, Md., ...
... MOUNTAIN VIEW, Calif., March 4 The Healthcare ... pleased to announce its 2009 Quarterly Analyst Briefing ... be held on Thursday, March 5, 2009 at ... industry has witnessed healthy growth and is experiencing ...
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... fourth quarter of 2008 was $334,041 compared to $174,071 for ... from the sale of PCT products and services was $233,256 ... $118,703 for the same period in 2007, a 97% increase. ...
Cached Biology Technology:Martek Announces First Quarter 2009 Financial Results 2Martek Announces First Quarter 2009 Financial Results 3Martek Announces First Quarter 2009 Financial Results 4Martek Announces First Quarter 2009 Financial Results 5Martek Announces First Quarter 2009 Financial Results 6Martek Announces First Quarter 2009 Financial Results 7Martek Announces First Quarter 2009 Financial Results 8Martek Announces First Quarter 2009 Financial Results 9Martek Announces First Quarter 2009 Financial Results 10Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 3Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 4Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 5Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 6Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 7Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 8
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Feb. 1, 2008) This months issue of ... methods to understand developmental processes in plants and flies. ... on the Web site for Cold Spring Harbor Protocols ... use of RNAi to investigate gene function in fruit flies. ...
... the role of a gene important to the embryonic ... coordination of differentiation of immature neural cells with the ... now, the mechanisms regulating these distinct cellular activities have ... published in the Feb. 15 issue of Development. ...
... Scientists at the University of Alabama at Birmingham ... uncover new details about the infectious potency of poxviruses, ... infections can subvert the bodys immune system. Having ... the discovery of new drugs to combat inflammation and ...
Cached Biology News:RNA-based methods for developmental studies are featured in Cold Spring Harbor Protocols 2Trainor Lab characterizes gene essential for prenatal development of nervous system 2Poxvirus potency uncovered in new atomic map 2
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: